

ASX ANNOUNCEMENT

29 July 2026

Quarterly Activities & Appendix 4C June 2026

- *Biome* delivers record annual (FY26) sales revenue and record consumer sell-through
 - June 2026 was the first month in which consumer sell-through of Activated Probiotics surpassed 100,000 units
 - \$23.9m FY26 annual sales revenue, up 30% vs FY25 (\$18.4m)
- *Biome* Daily is now the number one probiotic product in Australian pharmacy, by both units and dollar value¹
- Binding manufacturing agreement signed with Specialty Probiotics Australia (SPA) to bring the Activated Probiotics range onshore, a Vision 27 cornerstone requiring no capital investment, with the first commercial batch targeted for September 2026
- BMB18 patent application lodged during the quarter, for *Biome*'s proprietary probiotic strain
- BMB18 clinical trial expanded to its first international centre, Harokopio University of Athens, with participant recruitment commenced at both Athens and La Trobe University in June.
- Cash receipts of \$5.9m for the quarter, +\$1.1m on Q3 FY26 and +\$2.2m (61%) vs pcip
- Net operating cash inflow of \$708k for the quarter
- Cash balance increased to \$3.6m at 30 June 2026, +\$0.2m on Q3 FY26 and +\$0.8m vs pcip
- Debt reduced by \$1.0m vs pcip to \$1.9m drawn at 30 June 2026.

¹ IQVIATM Sell Out Service, VITAMINS & SUPPLEMENTS category, CHC3=PROBIOTICS, Australia Pharmacy, Total Value and Unit, 52 Weeks W/E 2026-06-27.

For personal use only

Microbiome health company **Biome Australia Limited** (ASX: BIO) (*‘Biome’* or *‘the Company’*) is pleased to provide its Appendix 4C and Activity Report for the quarter ended 30 June 2026 (“Q4 FY26”), closing a record year for both trading and financial performance for the Company.

Biome delivered record annual sales revenue in FY26. June 2026 was also the first month in which consumer sell-through of Activated Probiotics surpassed 100,000 units, a Company first. Annual sales revenue of \$23.9m for FY26 is an increase of 30% on FY25 (\$18.4m). This growth was driven by continued practitioner and pharmacy demand for the Activated Probiotics and Activated Therapeutics ranges, across both *Biome’s* domestic and international markets.

During the quarter, *Biome* received confirmation that Biome Daily is now the number one probiotic product in Australian pharmacy, by both units and dollar value.² This is a significant milestone for the Company’s flagship product. It also points to the opportunity still ahead both domestically and internationally. The rest of the Activated Probiotics and Activated Therapeutics range has real room to grow from an already strong base.

Full financial detail for the year, including profitability and margin, will be provided with *Biome’s* audited full-year results.

Cash receipts from customers were \$5.9m in Q4 FY26, up \$1.1m on Q3 FY26 and \$2.2m (61%) against Q4 FY25. This reflects both the overall growth in trading and continued discipline in working capital management. In Q4, the Company delivered a net operating cash inflow of \$708k and closed Q4 FY26 with \$3.6m in cash, an increase of \$0.2m from the previous quarter and \$0.8m, pcp.

Biome also continued to strengthen its balance sheet during the quarter, reducing drawn debt by \$1.0m relative to pcp, maintaining \$1.9m at 30 June 2026 (against total NAB facilities of \$5.0m), leaving \$3.1m of facility headroom available. This was driven by strong operating cash generation and disciplined capital management. It gives *Biome* substantial flexibility to fund continued growth, particularly as we commence onshore manufacturing from Q1 FY27.

During the quarter, *Biome* continued to invest in its proprietary intellectual property. Biome lodged a patent application for BMB18, its first wholly proprietary probiotic strain, and expanded the BMB18 human clinical trial

² Source: IQVIA Pharmacy Scan data, FY26. Ranking based on unit and dollar sales within the probiotic category in Australian pharmacy.

from a single site to a multi-centre international program. The trial is a randomised, double-blind, placebo-controlled study enrolling 240 participants. Harokopio University of Athens has joined as *Biome's* first international centre alongside La Trobe University in Melbourne, with recruitment commenced at both sites during the quarter. BMB18 is expected to further differentiate the Activated Probiotics range as it progresses through clinical evaluation.

During the quarter, *Biome* signed a binding commercial manufacturing agreement with Specialty Probiotics Australia (SPA) to progressively bring production of its Activated Probiotics range onshore, a cornerstone of the Company's Vision 27 strategy. The agreement requires no capital investment from *Biome*, with the first commercial batch targeted for September 2026 and the balance of the range transitioning over approximately 18 months. Onshore production is expected to deliver a structural improvement in cost of goods sold from the first commercial batch and to release working capital through lower inventory and the removal of extended international freight lead times, while adding an Australian-made advantage across the Company's export markets. *Biome* will retain its European supply partnerships to service EU markets, providing further supply-chain diversification.

Looking ahead, *Biome* expects 1H FY27 to be its highest revenue-generating half-year on record, supported by a number of new product launches across the Activated Probiotics range and continued growth in the Company's key international markets.

Biome Australia Managing Director and Founder Blair Vega Norfolk said:

"Q4 FY26 was a landmark quarter for Biome, capping off our strongest year yet. Record annual revenue, record consumer sell-through, and the momentum in our practitioner-led model all reflect the increasing scale of the business. We were also thrilled to learn that Biome Daily is now the number one probiotic product in Australian pharmacy, in both units and dollars. It is a proud moment, and only part of the story, with significant opportunity still ahead across the rest of the range."

We reduced debt and grew cash through the year while continuing to invest for growth, demonstrating that our growth remains highly capital efficient.

Alongside this, we invested in Biome's long-term competitive position. We signed our first onshore manufacturing agreement with SPA and expanded the BMB18 clinical trial to its first international centre in Athens, with



Biome Australia Limited
192-194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014

recruitment now underway at both sites. With a number of new product launches planned and our international markets continuing to build momentum, we expect 1H FY27 to be our highest revenue-generating half yet."

Quarterly Financial Update

Biome recorded a net operating cash inflow of \$708k for Q4 FY26, a significant improvement on both Q3 FY26 (net operating cash outflow of \$1,235k) and pcp (net operating cash outflow of \$485k). This result was underpinned by strong cash receipts from customers of \$5,942k for the quarter, which grew faster than the corresponding growth in operating payments.

The Company maintained a disciplined approach to operating expenditure throughout the quarter, closely managing its cost base while continuing to hold adequate safety stock to protect forecast growth levels in our traditionally highest quarter (FY Q1), against a backdrop of variable economic conditions and heightened international logistics and freight challenges. This approach reflects *Biome's* ongoing focus on working capital efficiency and positions the Company well ahead of the planned commencement of onshore manufacturing from Q1 FY27, which is expected to progressively reduce the Company's reliance on extended offshore supply chains and the associated inventory buffers. Payments for inventory and fulfilment were \$2,157k for the quarter.

On a cash basis for the quarter, direct brand marketing investment totalled \$799k. As a function of sales and in operating expense terms, direct brand marketing represented approximately 10.5% for Q4 FY26 and 7.5% for FY26.

Staff costs on a cash basis were \$1,736k, consistent with the Company's standard people-related expenditure, including sales incentives and bonus payments, in line with performance against targets.

Administration and corporate cash expenditure of \$328k for the quarter reflect overheads including corporate governance, compliance, insurance and professional services costs incurred in the normal course of operations, together with costs that are structural to *Biome's* practitioner-led distribution model.

Payments for property, plant and equipment of \$113k related primarily to the fit-out of *Biome's* new auditorium space, which will support practitioner

education seminars as part of the Company's practitioner-led engagement model.

Research and development payments were \$146k, consistent with *Biome's* continued investment in clinical research.

Investing activities in the quarter included \$128k in payments for intellectual property, including costs associated with the BMB18 patent application and clinical trial, and \$113k in payments for property, plant and equipment.

The Company continued to reduce net debt during the quarter, with \$223k of net loan repayments, reducing total drawn debt to \$1.9m at 30 June 2026 (30 June 2025: \$2.9m), against total available NAB facilities of \$5.0m.

The amount paid to Directors of the Company during the quarter was \$288,872 in fees, salaries and superannuation payments, as follows:

- Executive Director \$219,500
- Non-Executive Directors \$69,372

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Lauren Dwyer
corporate@biomeaustralia.com
(03) 9017 5800

Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of *Biome* (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of *Biome's* business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to *Biome* as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), *Biome* does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, *Biome* excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or



Biome Australia Limited
192-194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014

completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about *Biome* or which a prospective investor or purchaser may require in evaluating a possible investment in *Biome* or acquisition of securities in *Biome*.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

BIOME AUSTRALIA LIMITED (BIO)

ABN

51 627 364 014

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	5,942	24,178
1.2 Payments for		
(a) research and development	(146)	(458)
(b) inventory and fulfilment	(2,157)	(11,795)
(c) sales, advertising and marketing	(799)	(2,619)
(d) other operating receipts (costs)	(26)	(77)
(e) staff costs	(1,736)	(6,772)
(f) administration and corporate costs	(328)	(1,286)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(37)	(181)
1.6	Income taxes and FBT paid	(5)	(19)
1.7	Government grants and tax incentives	-	657
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	708	1,628

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(113)	(205)
	(d) investments	-	-
	(e) intellectual property	(128)	(284)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(241)	(489)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	354
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	525
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Payments for lease liabilities	(79)	(207)
3.6	Proceeds from/ (repayment of) borrowings	(223)	(1,005)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if relevant)	-	-
3.10	Net cash from / (used in) financing activities	(302)	(333)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,387	2,746
4.2	Net cash from / (used in) operating activities (item 1.9 above)	708	1,628

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(241)	(489)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(302)	(333)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	3,552	3,552

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,552	3,387
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,552	3,387

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000	
6.1	Aggregate amount of payments to related parties and their associates included in item 1	289	
6.2	Aggregate amount of payments to related parties and their associates included in item 2	Nil	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> The amount paid to Directors of the Company during the quarter was \$288,872 in fees, salaries and superannuation payments, as follows: - Executive Director \$219,500 - Non-Executive Directors \$69,372			
7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	5,000	1,900
7.2	Credit standby arrangements	Nil	n/a
7.3	Other (please specify)	Nil	n/a
7.4	Total financing facilities	5,000	1,900
7.5	Unused financing facilities available at quarter end	3,100	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

Biome Australia Trading Pty Ltd ("Biome Trading") a wholly owned subsidiary of The Company has entered into a \$5.0m secured debt facility ("Facility") with NAB for working capital purposes to fund future growth, comprising a \$3.5m NAB Invoice Finance Facility and a \$1.5m NAB Trade Finance Facility.

\$3.5m NAB Invoice Finance Facility

This facility will provide invoice funding for Biome's Australian accounts receivables. The current interest rate of the facility is 7.75%. The facility carries an application fee of \$12,250 plus a monthly facility fee of \$1,700. This is an ongoing facility with no set expiry date.

\$1.5m NAB Trade Refinance Facility

The current interest rate of the facility is 7.53% p.a. The facility carries an application fee of \$5,250 plus a facility fee of 1.3% p.a. This facility was set to expire on 27 February 2026 and was extended by a year, to 27 February 2027. The facility is secured by a General Security Agreement over the whole of Biome Trading's assets, a First ranking priority charge over the whole of Biome Trading's receivables (debtor) book and a Deed of Guarantee and Indemnity from the Company, supported by a General Security Agreement over the whole of the assets of the Company.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	708
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,552
8.3	Unused finance facilities available at quarter end (item 7.5)	3,100
8.4	Total available funding (item 8.2 + item 8.3)	6,652
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:29 July 2026.....

Authorised by:Authorised by the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.